Press Releases Jan 10, 2023 Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC Nov 30, 2022 Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR) Nov 09, 2022 Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress View all press releases Presentations & Events View all presentations & events Form 8937 View Form 8937 - September 30, 2015 View Form 8937
Jan 10, 2023 Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC
Nov 30, 2022 Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)
Nov 09, 2022 Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress